Use of Treprostinil to treat neuropathic diabetic foot ulcers

ABSTRACT

The present invention describes novel methods for using 9-deoxy-2′,9-α-methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandin F 1  (also known as Treprostinil) or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of foot ulcers in subjects with diabetic neuropathy. The invention also relates to kits for treatment and/or prevention of foot ulcers, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

The present application claims priority to U.S. provisional patentapplication No. 60/561,157, filed Apr. 12, 2004, incorporated hereby byreference in its entirety.

BACKGROUND OF THE INVENTION

The invention relates to the use of9-deoxy-2′,9-α-methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandinF₁ (hereafter “Treprostinil”) or its derivative, or a pharmaceuticallyacceptable salt thereof, to treat foot ulcers, for example, in patientswith diabetic neuropathy. This invention also relates to kits to be usedfor this purpose.

Treprostinil, also known as UT-15, is a known compound disclosed in U.S.Pat. No. 4,306,075 in example 33. Treprostinil is a synthetic analog ofepoprostenol, a prostaglandin F₁. The activities ascribed to the variouscompounds of this patent include inhibition of smooth muscle cellproliferation, inhibition of platelet aggregation, inhibition ofcytokine secretion, reduction of gastric secretion, vasodialation andbronchodilation.

U.S. Pat. No. 5,153,222 discloses the use of Treprostinil and relatedcompounds to treat pulmonary hypertension. U.S. Pat. No. 6,054,486discloses the use of Treprostinil and related compounds to treatperipheral vascular disease, such as peripheral arterial occlusivedisease and intermittent claudication. Patterson et al., Amer. J. ofCardiology, 75: 26A-33A (1995), have shown vasodilator effects ofTreprostinil in patients with class III or class IV heart failure.

Clapp et al., Am. J. Respir. Cell. Mol. Biol., 26 (2): 194-201 (2002),have shown that Treprostinil inhibits proliferation of human pulmonaryarterial smooth muscle cells. Raychaudhuri et al., J. Biol. Chem., 277(36): 33344-8 (2002), have disclosed that Treprostinil inhibitsinflammatory cytokine (tumor necrosis factor-α, interleukin-1β,interleukin-6, and granulocyte macrophage colony-stimulating factor)secretion and gene expression by human alveolar macrophages.

Approximately 15% of all diabetes patients will develop a foot ulcer atsome point in their lives, see, e.g., Jeffccoate, W & Harding, K., 2003.Diabetic Foot Ulcers. The Lancet, 362; 154-51, incorporated hereby byreference in its entirety. There are many pathways for a diabetic footulcer to develop. In general, approximately 20% of patients withdiabetes will develop a foot ulcer primarily as a result of inadequatearterial blood flow (peripheral arterial disease), 50% from diabeticneuropathy, and 30% from a combination of lower limb ischemia anddiabetic neuropathy. Since not all methods suitable for treatingischemic lesions can necessarily be used to treat ulcers caused bydiabetic neuropathy, the need exits to identify viable methods, as wellas kits, that can be used to prevent and treat such ulcers. See, e.g.,Margolis, D. Hoffstad, O, Allen-Taylor, L., and Berlin, J., 2002.Diabetic Neuropathic Foot Ulcers: The association of the wound size,wound duration and wound healing. Diabetes Care 25:1835-39, incorporatedhereby by reference in its entirety.

In addition, the differences in healing between a vascular leg ulcer(including the foot) and a diabetic foot ulcer can be found in Kantor J,Margolis D. Expected Healing Rates for Chronic Wounds. Wounds 12(6):155-158, 2000. For example, in a study with 260 patients withvascular leg ulcers (VLU) and 586 patients with diabetic foot ulcers(DFU), 32% VLU failed to heal after 24 weeks of good ulcer care, while67% DFU failed to heal after 20 weeks of good ulcer care. Otherreferences distinguishing these different ulcers can be found inWatkins, P., Brit. Med. J., 326:977-979 (2003), TransAtlanticIntersociety Consensus (TASC), J. Vasc. Surgery, v. 31, NI part 2, pageS199 (2000), and Greenhalgh D G, Clin. Plast. Surg., 30:37-45 (2003),which are incorporated herein by reference in their entirety.

Diabetic neuropathy is a condition in which nerve damage from diabetescaused decreased sensation in the legs and feet. If a patient developsan open area from pressure or from a cut, the patient may not even feelthe sore. Left untreated, the damaged area can develop a diabetic footulcer that is susceptible to polymicrobial infection that spreadsrapidly and causes overwhelming tissue destruction. This infectionprocess is the main reason for major amputation following ulceration inpatients with predominantly neuropathic ulceration. Traditionaltreatment approaches to foot ulcers include desloughing and debridement,pressure relief (e.g., rest, special footwear and shoe inserts andcasting), antibiotic treatment for infection and wound dressing.Although certain types of dressings sometimes can help to aid healing ofthe lesions, these treatments are often unsuccessful.

Neuropathic diabetic foot ulcers can be extremely painful, debilitating,and heal slowly. Thus, the need exists to identify viable methods, aswell as kits, that can be used to prevent and treat such ulcers. Thepresent invention satisfies this need and provides related advantages aswell.

SUMMARY OF THE INVENTION

The pathophysiology of diabetic foot ulcers is described as first havingneuropathic changes uniquely associated with diabetes mellitus, andmicroangiopathy. Administration of Treprostinil or its derivativestreats neuropathic diabetic foot ulcers. Treprostinil is well suited forsuch use because the compound is a stable analogue of prostaglandin, canbe used in intravenous administration, is not degraded when it passesthrough the lungs, and has a long biological half-life.

Accordingly, the present invention provides for the treatment ofneuropathic diabetic foot ulcers and/or the treatment of symptomsassociated with neuropathic diabetic foot ulcers in a mammal, comprisingadministering to a mammal in need thereof an effective amount ofTreprostinil or a derivative thereof or a pharmaceutically acceptablesalt. In one embodiment, Treprostinil or a derivative thereof isadministered sufficiently early in a disease state to provide acytoprotective effect. The present invention also provides for kits foraccomplishing this purpose.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The inventors believe that therapies that enhance cutaneous blood flow(i.e., to the skin), by increasing blood flow through smaller vesselsand capillaries, are effective in treating and preventing neuropathicdiabetic foot ulcers. One type of vascular change that is seen indiabetes patients is nonocculusive microcirculatory dysfunctioninvolving capillaries and arterioles. Thus, structural changes in themicrocirculation, including capillary basement membrane thickening andabnormal endothelial function, are associated with patients that havediabetes.

Prostacyclins are small molecules that have been previously shown tocause dilation of large blood vessels, relaxation of smooth muscle,inhibition of smooth muscle proliferation, as well as inhibition ofplatelet aggregation. Similar actions by Treprostinil at themicrovascular level and on capillaries near the skin are believed tohelp enhance cutaneous blood flow and heal and/or prevent neuropathicdiabetic foot ulcers.

Diabetic neuropathic foot ulcers are sometimes characterized as notbeing associated with pain. A foot pulse is usually present and theulcer has a punched out appearance. The sore is often on the sole oredge of the foot and calluses are present. Other characteristics of thediabetic neuropathic foot can include a loss of sensation, reflexes, andvibration, AV shunting of the blood flow, dilated veins, dry/warm skintemperature, and skin appearance that is red in color. There typicallyare bone deformities.

This is in contrast to a diabetic neuroischemic ulcer, which is painfuland has an irregular appearance around the margins. A foot pulse isusually absent and the ulcer is commonly on the toes. Calluses areabsent or infrequent, blood flow is decreased, veins are collapsed, theskin feels cold and the skin color is pale or cyanosed. There aretypically no bony deformities.

The present invention relates to methods for treating and/or preventingneuropathic diabetic foot ulcers comprising administering to a subject,preferably a human being, in need thereof an effective amount ofTreprostinil and/or a derivative thereof and/or a pharmaceuticallyacceptable salt. Suitable derivatives include acid derivatives,pro-drugs, sustained release forms, inhaled forms and oral forms ofTreprostinil, including those disclosed in U.S. Pat. No. 6,521,212 andco-pending Ser. No. 60/472,407. In some embodiments, pain and/or othersymptoms associated with neuropathic diabetic foot ulcers are reduced,eliminated or prevented upon administration of an effective amount ofTreprostinil, and/or its pharmaceutically acceptable salts andderivatives thereof.

The present invention also relates to kits for accomplishing suchtreatment or prevention of neuropathic diabetic foot ulcers. Theinvention includes a kit for treatment and/or prevention of foot ulcersin a subject with diabetic neuropathy, comprising (i) an effectiveamount of Treprostinil, its pharmaceutically acceptable salts, and/oracid derivatives thereof, (ii) one or more pharmaceutically acceptablecarriers and/or additives, and (iii) instructions for use in treatingand/or preventing neuropathic diabetic foot ulcers.

Unless otherwise specified, the term “a” or “an” used herein shall mean“one or more.”

As used herein, the phrase “instructions for use” shall mean anyFDA-mandated labeling, instructions, or package inserts that relate tothe administration of Treprostinil for the purpose of treating and/orpreventing neuropathic diabetic foot ulcers. For example, instructionsfor use may include, but are not limited to, indications for neuropathicdiabetic foot ulcers, indications for specific symptoms associated withneuropathic diabetic foot ulcers, such as pain, that can be amelioratedby Treprostinil, and recommended dosage amounts for subjects sufferingfrom neuropathic diabetic foot ulcers.

The term “acid derivative” is used herein to describe C1-4 alkyl estersand amides, including amides wherein the nitrogen is optionallysubstituted by one or two C1-4 alkyl groups.

The invention also includes bioprecursors or “pro-drugs” ofTreprostinil, that is, compounds which are converted in vivo toTreprostinil or its pharmaceutically active derivatives thereof.

Further aspects of the present invention are concerned with the use ofTreprostinil, or a pharmaceutically acceptable salt or acid derivativethereof, in the manufacture of a medicament for treatment or preventionof foot ulcers in subjects with diabetic neuropathy.

The present invention encompasses methods of using Treprostinil sodium,currently marketed under the trade name of REMODULIN®. The FDA hasapproved Treprostinil sodium for the treatment pulmonary arterialhypertension by injection of dose concentrations of 1.0 mg/mL, 2.5mg/mL, 5.0 mg/mL and 10.0 mg/mL. The chemical structure formula forTreprostinil sodium is:

Treprostinil sodium is sometimes designated by the chemical names: (a)[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]aceticacid; or (b)9-deoxy-2′,9-α-methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandinF₁. Treprostinil sodium is also known as: UT-15; LRX-15; 15AU81;UNIPROST™; BW A15AU; and U-62,840. The molecular weight of Treprostinilsodium is 390.52, and its empirical formula is C₂₃H₃₄O₅.

The present invention extends to methods of using physiologicallyacceptable salts of Treprostinil that may be used in the preparation ofthe pharmacologically active compounds of the invention.

The physiologically acceptable salts of Treprostinil include saltsderived from bases. Base salts include ammonium salts, alkali metalsalts such as those of sodium and potassium, alkaline earth metal saltssuch as those of calcium and magnesium, salts with organic bases such asdicyclohexylamine and N-methyl-D-glucamine, and salts with amino acidssuch as arginine and lysine.

Quaternary ammonium salts can be formed, for example, by reaction withlower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides,bromides, and iodides, with dialkyl sulphates, with long chain halides,such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, andiodides, and with aralkyl halides, such as benzyl and phenethylbromides.

The amount of Treprostinil, or a physiologically acceptable salt or acidderivative thereof, which is required in a medication or diagnostic aidaccording to the invention to achieve the desired effect will depend ona number of factors, such as the specific application, the nature of theparticular compound used, the mode of administration, the concentrationof the compound used, and the weight and condition of the patient. Adaily dose per patient for treatment or prevention of neuropathicdiabetic foot ulcers may be in the range 25 μg to 250 mg; 0.5 μg to 2.5mg, or 7 μg to 285 μg, per day per kilogram bodyweight. For example, anintravenous dose in the range 0.5 μg to 1.5 mg per kilogram bodyweightper day may conveniently be administered as an infusion of from 0.5 ngto 1.0 μg per kilogram bodyweight per minute. One possible dosage is 2.5ng/kg/min, increased over 12 weeks by an amount of 2.50 ng/kg/min eachweek, until a target dose, such as 15 ng/kg/min, is reached. Infusionfluids suitable for this purpose contain, for example, from 10 ng to 1μg per milliliter. Ampoules for injection contain, for example, from 0.1μg to 1.0 mg and orally administrable unit dose formulations, such astablets or capsules, contain, for example, from 0.1 to 100 mg, typicallyfrom 1 to 50 mg. For diagnostic purposes, a single unit dose formulationmay be administered. In the case of physiologically acceptable salts,the weights indicated above refer to the weight of the active compoundion, that is, the ion derived from Treprostinil.

In the manufacture of a medicament or diagnostic aid according to theinvention, hereinafter referred to as a “formulation”, Treprostinil andits physiologically acceptable salts and acid derivatives may be admixedwith, inter alia, an acceptable carrier. The carrier must, of course, beacceptable in the sense of being compatible with any other ingredientsin the formulation and must not be deleterious to the subject. Thecarrier may be a solid or a liquid, or both, and is preferablyformulated with the compound as a unit-dose formulation, for example, atablet, which may contain from 0.05% to 95% by weight of the activecompound. One or more of Treprostinil and/or its physiologicallyacceptable salts or acid derivatives may be incorporated in theformulations of the invention, which may be prepared by any of the wellknown techniques of pharmacy for admixing the components.

In addition to Treprostinil, other pharmacologically active substancesmay be present in the formulations of the present invention which areknown to be useful for treating and/or preventing foot ulcers inpatients with diabetic neuropathy. For example, the compounds of theinvention may be present in combination with analgesics to treat pain,dressing changes, vasodilator medications, and topical or oralantibiotics.

The formulations of the invention include those suitable for parenteral(e.g., subcutaneous, intramuscular, intradermal, or intravenous), oral,inhalation (in solid and liquid forms), rectal, topical, buccal (e.g.,sub-lingual) and transdermal administration, although the most suitableroute in any given case may depend on the nature and severity of thecondition being treated and on the nature of the particular form ofTreprostinil, as well as the physiologically acceptable salt or acidderivative thereof, which is being used.

Formulations of the present invention suitable for parenteraladministration conveniently comprise sterile aqueous preparations ofTreprostinil, or a physiologically acceptable salt or acid derivativethereof, where the preparations may be isotonic with the blood of theintended recipient. These preparations may be administered by means ofsubcutaneous injection, although administration may also be effectedintravenously or by means of intramuscular or intradermal injection.Such preparations may conveniently be prepared by admixing the compoundwith water or a glycine or citrate buffer and rendering the resultingsolution sterile and isotonic with the blood. Injectable formulationsaccording to the invention may contain from 0.1 to 5% w/v of activecompound and may be administered at a rate of 0.1 ml/min/kg.Alternatively, the invention may administered at a rate of 0.625 to 50ng/kg/min. Alternatively, the invention may be administered at a rate of10 to 15 ng/kg/min.

Formulations suitable for oral administration may be presented indiscrete units, such as capsules, cachets, lozenges, or tablets, eachcontaining a predetermined amount of Treprostinil or a physiologicallyacceptable salt or acid derivative thereof; as a powder or granules; asa solution or a suspension in an aqueous or non-aqueous liquid; or as anoil-in-water or water-in-oil emulsion. Such formulations may be preparedby any suitable method of pharmacy which includes the step of bringinginto association the active compound and a suitable carrier (which maycontain one or more accessory ingredients).

In general, the formulations of the invention are prepared by uniformlyand intimately admixing the active compound with a liquid or finelydivided solid carrier, or both, and then, if necessary, shaping theresulting mixture. For example, a tablet may be prepared by compressingor molding a powder or granules containing the active compound,optionally with one or more accessory ingredients. Compressed tabletsmay be prepared by compressing, in a suitable machine, the compound in afree-flowing form, such as a powder or granules optionally mixed with abinder, lubricant, inert diluent, and/or surface active/dispersingagent(s). Molded tablets may be made by molding, in a suitable machine,the powdered compound moistened with an inert liquid binder.

Formulations suitable for buccal (sub-lingual) administration includelozenges comprising Treprostinil, or a physiologically acceptable saltor acid derivative thereof, in a flavored base, usually sucrose andacacia or tragacanth; and pastilles comprising the compound in an inertbase such as gelatin and glycerin or sucrose and acacia.

Formulations suitable for rectal administration are preferably presentedas unit dose suppositories. These may be prepared by admixingTreprostinil, or a physiologically acceptable salt or acid derivativethereof, with one or more conventional solid carriers, for example,cocoa butter, and then shaping the resulting mixture.

Formulations suitable for topical application to the skin preferablytake the form of an ointment, cream, lotion, paste, gel, spray, aerosol,or oil. Carriers which may be used include vaseline, lanoline,polyethylene glycols, alcohols, and combinations of two or more thereof.The active compound is generally present at a concentration of from 0.1to 15% w/w, for example, from 0.5 to 2% w/w. Formulations fortransdermal administration may be delivered by iontophoresis (see, forexample, Pharmaceutical Research, 3 (6): 318 (1986)) and typically takethe form of an optionally buffered aqueous solution of Treprostinil orof a salt or acid derivative thereof. Suitable formulations comprisecitrate or bis/tris buffer (pH 6) or ethanol/water and contain from 0.1to 0.2M active ingredient.

The compounds of the present invention are conveniently prepared bymethods the same as or analogous to those described in U.S. Pat. No.4,306,075, U.S. Pat. No. 6,528,688 and U.S. Pat. No. 6,441,245.

Additional embodiments are within the scope of the invention. Forexample, in one embodiment, a method for treating and/or preventing afoot ulcer in a subject (such as human being) with diabetic neuropathycomprises administering to a subject in need thereof an effective amountof Treprostinil or its derivative, or a pharmaceutically acceptable saltthereof.

In another embodiment, a kit for treatment and/or prevention of a footulcer in a subject with diabetic neuropathy, comprises (i) an effectiveamount of Treprostinil or its derivative, or a pharmaceuticallyacceptable salt thereof, (ii) one or more pharmaceutically acceptablecarriers and/or additives, and (iii) instructions for use in treating orpreventing a foot ulcer in a subject with diabetic neuropathy.

In certain method embodiments, administering to a subject in needthereof an effective amount of Treprostinil or its derivative, or apharmaceutically acceptable salt thereof results in pain or othersymptoms associated with a foot ulcer being reduced, eliminated orprevented.

In certain method embodiments, the Treprostinil or its derivative, or apharmaceutically acceptable salt thereof, is administeredsubcutaneously, by continuous subcutaneous infusion, intravenously, inan orally available form selected from the group consisting of tabletsand capsules, and/or by inhalation. In other embodiments, the effectiveamount of Treprostinil or its derivative, or a pharmaceuticallyacceptable salt thereof, is at least 1.0 ng/kg of body weight/min.

In certain kit embodiments, the Treprostinil or its derivative, or apharmaceutically acceptable salt thereof, is in a form suitable forsubcutaneous administration, continuous subcutaneous infusion,intravenously administration or inhalation. In other kit embodiments,the Treprostinil or its derivative, or a pharmaceutically acceptablesalt thereof, is in an orally available form selected from the groupconsisting of tablets and capsules. In another kit embodiment, theeffective amount of Treprostinil or its derivative, or apharmaceutically acceptable salt thereof, is at least 1.0 ng/kg of bodyweight/min.

The use of Treprostinil for treating foot ulcers in patients withdiabetic neuropathy can be illustrated in more details by the followingexample, however, it should be understood that the present invention isnot limited thereto.

EXAMPLE 1 Treprostinil Sodium (Remodulin®) is Safe and Promotes IschemicWound Healing and Relief of Rest Pain in Patients with Diabetes andPeripheral Arterial Disease

INTRODUCTION: The purpose of this open-label study is to evaluate thesafety and efficacy of treprostinil sodium, a stable prostacyclinanalogue, in ten patients with PAD, diabetes and inoperable ischemicfoot ulcers.

METHODS: Treprostinil sodium was administered as a continuoussubcutaneous infusion beginning at 2.5 ng/Kg/Min and titrated to highesttolerated dose for 12 weeks. Patients were monitored for adverse events,wound healing, skin perfusion pressure and ischemic rest pain.RESULTS: Seven patients have completed the trial to-date. No seriousadverse events attributed to treprostinil occurred during the trial. Theonly drug related side effect reported was mild to moderate infusionsite pain. Two patients experienced complete healing. Two patientsexperienced partial healing. Five experienced complete resolution ofrest pain.CONCLUSIONS: Treprostinil sodium is safe and has a positive effect onischemic rest pain, skin perfusion, and wound healing.

EXAMPLE 2 Enhancement of Peri-Wound Oximetric and Laser Doppler Signalswith Treprostinil Sodium (Remodulin®) in Ischemic Limbs

INTRODUCTION: A case-controlled trial examining the effects oftreprostinil sodium (Remodulin®), by continuous subcutaneous infusion,was performed in diabetic patients with recalcitrant lower extremitywounds. The known vasodilator and platelet-aggregation inhibitorproperties of treprostinil sodium warranted its evaluation as anadjuvant to wound healing in ischemic extremities. The primary endpointswere wound healing and limb salvage. Amongst the secondary endpointswere resting peri-wound transcutaneous oximetry (T_(c)PO₂) and laserDoppler analysis (LD) and the response of T_(c)PO₂ and LD to an oxygenchallenge at ambient or elevated pressure. If treprostinil sodiumreduces inflow resistance distal to the pre-capillary sphincter, theΔ_(p)O₂ between the hypoxic wound center and the inflow blood shouldincrease both in magnitude and in the slope of that difference. Thiswould be the physiologic basis for the augmentation of the hypoxicsignal.METHODS: The seven enrolled patients were diabetics with non-healingwounds present (>3 months) in critically ischemic lower extremities(Fontaine Stage III-IV or Rutherford Stage 4, 5 or 6). The treprostinilsodium (Remodulin®) was given by continuous subcutaneous infusion forthe study period of 6 weeks. Candidacy for hyperbaric oxygen treatmentwas an exclusion criterion (patient refusal, logistical constraints or arecently completed HBO₂ course). Hyperbaric oxygen exposures wereincluded as diagnostic/monitoring indices. T_(c)PO₂/LD measurements weremade at ambient pressure and at 1, 2.0 or 2.4 atmospheres absolute (ATA)before Remodulin® was begun and at various points during drug infusion.RESULTS: T_(c)PO₂/LD data show:1—All patients but one (the individual with no LD/T_(c)PO₂ improvementon Remodulin®) demonstrated healing in wounds with a mean interval of“healing arrest” of 10.5 months.2—All patients (with exception of one) demonstrated improvement inresting peri-wound T_(c)PO₂ values (⇑44 to 176%) and in LD signals (236%increase in thermal stimulation response) on Remodulin®.3—The slope of the T_(c)PO₂ response to O₂-challenge at 1, 2.0 and 2.4ATA increased 56 to 345%.CONCLUSIONS: The ability of treprostinil sodium to improve tissue bloodflow in chronically ischemic wounds is evident from the elevation inresting peri-wound T_(c)PO₂, the magnification of the O₂ challengeresponse at ambient and elevated pressures and the improvement in thelaser Doppler signals. This agent can be another adjunct in thetreatment of non-healing, ischemic wounds and is clearly synergisticwith the effects of hyperbaric oxygen treatment.

EXAMPLE 3 Administration of Treprostinil to Humans with DiabeticNeuropathy Suffering from Foot Ulcers

Diabetic neuropathy patients having at least one ulcer (i.e., small soreor area of tissue gangrene) present on a foot are dosed with increasingamounts of Treprostinil over 12 weeks. The medication is delivered by asmall pump that is connected to a catheter placed under the skin. Inthis manner, increasing dosages of Treprostinil are administered topatients by chronic continuous subcutaneous infusion.

Specifically, a 1.0 mg/mL formulation of Treprostinil sodium(REMODULIN®) is administered subcutaneously using a standardmicro-infusion, positive-pressure infusion pump designed forsubcutaneous drug delivery (Mini-Med). Patients receive an initial doseof 2.5 ng/kg/min of study drug. If, in a given patient, a dose of 2.5ng/kg/min is not tolerated (e.g., persistent headache, nausea, emesis,restlessness, anxiety or severe pain at infusion site that cannot beadequately managed by medication or topical treatment), the dose isreduced to 1.25 ng/kg/min. Patients are maintained at 2.5 ng/kg/min (or1.25 ng/kg/min if 2.5 ng/kg/min is not tolerated) during Week 1. Afterthat, the dose is raised by 2.50 ng/kg/min each week until not toleratedor once a target dose is reached.

Dosing is increased weekly unless not tolerated by the patient. Weeklydose increases do not exceed 2.50 ng/kg/min each. One example of atarget dose is 15 ng/kg/min. The minimum dose is usually not less than0.625 ng/kg/min. After completion of the Week 12 treatment, druginfusion are terminated by gradual reduction of the infusion rate (overa period of 1-4 hours, as clinically indicated) until a rate of 0ng/kg/min is reached.

Patients receiving the above-described treatment experience fewer newfoot ulcers associated with diabetic neuropathy, and see a reduction inthe number, size and severity of foot ulcers present before treatment.The administration of Treprostinil treats and prevents foot ulcers inpatients with diabetic neuropathy.

It will be apparent to those skilled in the art that variousmodifications and variations can be made to the compositions andprocesses of this invention. Thus, it is intended that the presentinvention cover such modifications and variations, provided they comewithin the scope of the appended claims and their equivalents.

The disclosure of all publications cited above are expresslyincorporated herein by reference in their entireties to the same extentas if each were incorporated by reference individually.

1. A method for treating a diabetic neuropathic foot ulcer, comprisingadministering to a subject with diabetic neuropathy in need thereof aneffective amount of Treprostinil or its derivative, or apharmaceutically acceptable salt thereof, wherein said derivative is asustained release form of Treprostinil, an inhaled form of Treprostinil,an oral form of Treprostinil or an acid derivative of Treprostinil,wherein the subject has diabetic neuropathy but not peripheral vasculardisease.
 2. The method of claim 1, wherein said administering results insymptoms associated with the diabetic neuropathic foot ulcer in thesubject being reduced or eliminated.
 3. The method of claim 1, whereinsaid administering is administering to the subject an effective amountof a pharmaceutically acceptable salt of Treprostinil.
 4. The method ofclaim 1, wherein the subject is a human being.
 5. The method of claim 1,wherein said administering is subcutaneous administering.
 6. The methodof claim 1, wherein said administering is administering by continuoussubcutaneous infusion.
 7. The method of claim 1, wherein saidadministering is intravenous administering.
 8. The method of claim 1,wherein said administering is administering in an orally available formselected from the group consisting of tablets and capsules.
 9. Themethod of claim 1, wherein said administering is administering byinhalation.
 10. The method of claim 1, wherein the effective amount isat least 1.0 ng/kg of body weight/min.
 11. A method for reducing oreliminating a pain associated with or caused by a diabetic neuropathicfoot ulcer comprising administering to a subject with diabeticneuropathy in need thereof an effective amount of Treprostinil or itsderivative, or a pharmaceutically acceptable salt thereof, wherein saidderivative is a sustained release form of Treprostinil, an inhaled formof Treprostinil, an oral form of Treprostinil or an acid derivative ofTreprostinil, wherein the subject has diabetic neuropathy but notperipheral vascular disease.
 12. The method of claim 11, wherein saidadministering is administering to the subject an effective amount of apharmaceutically acceptable salt of Treprostinil.
 13. The method ofclaim 11, wherein the subject is a human being.
 14. The method of claim11, wherein said administering is subcutaneous administration.
 15. Themethod of claim 11, wherein said administering is administering bycontinuous subcutaneous infusion.
 16. The method of claim 11, whereinsaid administering is intravenous administering.
 17. The method of claim11, wherein said administering is administering in an orally availableform selected from the group consisting of tablets and capsules.
 18. Themethod of claim 11, wherein said administering is administering byinhalation.
 19. The method of claim 11, wherein the effective amount isat least 1.0 ng/kg of body weight/min.
 20. The method of claim 1,wherein said administering comprises orally administering to the subjectan oral formulation comprising diethanolamine salt of treprostinil. 21.The method of claim 11, wherein said administering comprises orallyadministering to the subject an oral formulation comprisingdiethanolamine salt of treprostinil.